These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 36200096)
21. Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report. Li J; Shui Z; Ouyang Q Ann Palliat Med; 2021 Sep; 10(9):10124-10129. PubMed ID: 34628933 [TBL] [Abstract][Full Text] [Related]
22. The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic HER2-positive breast cancer. Yang C; Shangguan C; Lou G; Qu Q Ann Palliat Med; 2022 Jan; 11(1):332-338. PubMed ID: 35144424 [TBL] [Abstract][Full Text] [Related]
23. Gastric Cancer Harboring an Ding K; Chen X; Li Y; Li W; Ye Y; He T; Wang W; Zhang H Onco Targets Ther; 2021; 14():545-550. PubMed ID: 33500629 [TBL] [Abstract][Full Text] [Related]
24. Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study. Hua Y; Li W; Jin N; Cai D; Sun J; Sun C; Yang F; Wu X; Huang X; Wang B; Yin Y Ther Adv Med Oncol; 2022; 14():17588359221085232. PubMed ID: 35356262 [TBL] [Abstract][Full Text] [Related]
25. Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: A case report. Dai J; Chen Y; Tang C; Wei X; Gong Y; Wei J; Gu D; Chen J Medicine (Baltimore); 2020 Jun; 99(25):e20809. PubMed ID: 32569228 [TBL] [Abstract][Full Text] [Related]
26. Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials. Mao S; Yang S; Liu X; Li X; Wang Q; Zhang Y; Chen J; Wang Y; Gao G; Wu F; Jiang T; Zhang J; Yang Y; Lin X; Zhu X; Zhou C; Ren S Exp Hematol Oncol; 2023 Jun; 12(1):53. PubMed ID: 37296463 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of pyrotinib and radiotherapy Chen J; Zhang H; Zhou J; Wu Z; Wu X; Zhang S; Jiang Z; Wang T Ann Transl Med; 2022 Nov; 10(22):1228. PubMed ID: 36544628 [TBL] [Abstract][Full Text] [Related]
28. Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients. Liu B; Yi Z; Guan Y; Ouyang Q; Li C; Guan X; Lv D; Li L; Zhai J; Qian H; Xu B; Ma F; Zeng Y Cancer Med; 2022 Jul; 11(14):2767-2778. PubMed ID: 35393784 [TBL] [Abstract][Full Text] [Related]
29. Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial. Song Z; Lv D; Chen SQ; Huang J; Li Y; Ying S; Wu X; Hua F; Wang W; Xu C; Bei T; Gao C; Sun Z; Zhang Y; Lu S Clin Cancer Res; 2022 Feb; 28(3):461-467. PubMed ID: 34753778 [TBL] [Abstract][Full Text] [Related]
30. Remarkable Response of Li HS; Yang LL; Zhang MY; Cheng K; Chen Y; Liu JY Front Oncol; 2020; 10():548867. PubMed ID: 33194604 [TBL] [Abstract][Full Text] [Related]
31. Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report. Ni J; Si XY; Zhang L Thorac Cancer; 2021 Apr; 12(8):1244-1247. PubMed ID: 33655632 [TBL] [Abstract][Full Text] [Related]
32. Metastatic brain tumors respond favorably to pyrotinib in a HER2-positive breast cancer following failure using trastuzumab. Yao JH; Xie ZY; Li M; Zhang ML; Ci HF; Yang Y Am J Transl Res; 2020; 12(9):5874-5881. PubMed ID: 33042466 [TBL] [Abstract][Full Text] [Related]
33. Pyrotinib treatment on HER2-positive gastric cancer cells promotes the released exosomes to enhance endothelial cell progression, which can be counteracted by apatinib. Gao Z; Song C; Li G; Lin H; Lian X; Zhang N; Cao B Onco Targets Ther; 2019; 12():2777-2787. PubMed ID: 31114227 [No Abstract] [Full Text] [Related]
34. Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis. Mao X; Lv P; Gong Y; Wu X; Tang P; Wang S; Zhang D; You W; Wang O; Zhou J; Li J; Jin F Front Oncol; 2022; 12():855512. PubMed ID: 35463365 [TBL] [Abstract][Full Text] [Related]
35. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Pyrotinib in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Multicenter, Retrospective, Real-World Study. Zhang X; Li Z; Han L; Lv Z; Teng Y; Cui X; Zhou C; Wu H; Fang W; Xu L; Zhao S; Song C; Zheng Y; Gao T; Li M Onco Targets Ther; 2022; 15():1067-1078. PubMed ID: 36199295 [TBL] [Abstract][Full Text] [Related]
37. HER2-positive breast cancer progresses rapidly after pyrotinib resistance: acquired RET gene fusion and TP53 gene mutation are potential reasons. Jiang F; Lai J; Zhuo X; Liu L; Yang Y; Zhang J; Zhao J; Xu W; Wang J; Wang C; Fu G Anticancer Drugs; 2023 Nov; 34(10):1196-1201. PubMed ID: 36689646 [TBL] [Abstract][Full Text] [Related]
38. Response to Anti-HER2-Based Treatment in a Patient with Bladder Adenocarcinoma Harboring Wang X; Hu W; Xie L Onco Targets Ther; 2020; 13():4249-4255. PubMed ID: 32547059 [TBL] [Abstract][Full Text] [Related]
39. Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial. Wang C; Lin Y; Zhou Y; Mao F; Zhu H; Guan J; Zhang X; Shen S; Huang X; Chen C; Yao R; Zhao J; Sun Q BMC Cancer; 2020 Jul; 20(1):653. PubMed ID: 32660609 [TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer. Wen HN; Liu YX; Xu D; Zhao KJ; Jiao Z Eur J Pharm Sci; 2021 Apr; 159():105729. PubMed ID: 33484815 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]